Saudi Sadara to shut cracker on Wednesday
by ChemOrbis Editorial Team - content@chemorbis.com
According to Reuters, Saudi Arabia’s Sadara Chemical will shut its 1.5 million tons/year mixed-feed cracker in Jubail for a scheduled maintenance. The company, which is a joint venture between Dow and Saudi Aramco, started up the cracker in August, 2016.
The company’s three polyethylene plants, which have a combined capacity of 1.1 million tons/year, will also be reportedly shut for maintenance during the same period. According to earlier reports, the commissioning of these PE plants was expected to be completed by the end of 2016 while some players were hearing PE cargoes from Sadara being pre-marketed in Southeast Asia and Turkey.
The maintenance at the cracker is expected to start on December 28, Wednesday and last for six weeks.
The company’s three polyethylene plants, which have a combined capacity of 1.1 million tons/year, will also be reportedly shut for maintenance during the same period. According to earlier reports, the commissioning of these PE plants was expected to be completed by the end of 2016 while some players were hearing PE cargoes from Sadara being pre-marketed in Southeast Asia and Turkey.
The maintenance at the cracker is expected to start on December 28, Wednesday and last for six weeks.
More free plastics news
Plastic resin (PP, LDPE, LLDPE ,HDPE, PVC, GPS; HIPS, PET, ABS) prices, polymer market trends, and more...- Asian PS, ABS markets shoot up on production upsets, soaring styrene
- Upsurge continues to wreak havoc on Turkey’s PP, PE markets
- PVC rally roars back in Asia as supply worries mount
- China PP, PE markets join global rally after Lunar New Year holiday
- PE, PP and PVC supply crunch exacerbated on US absence, traditional trade flows upended
- European PP, PE markets set for 5th bullish month as shortage bites
- Turkey shattered as PP prices shoot up to surreal levels
- Polymer markets face one of most chaotic times
- Turnaround season set to get underway in Asia
- Crude oil heals COVID-inflicted wounds; now what lies ahead?
